secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001213900-25-103772
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026
-----------------------------------------------------------------------------

- EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
- 2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.
- US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.
- Estimates 35% European population coverage through intended distribution channels.
- Targets $10.5B tissue oxygen market and >500M glucose monitoring population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/0001213900-25-103772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025103772/ea0263091-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-103772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer